

REPOS THERAPEUTICS INC.

Form 8-K

January 22, 2007

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 01/22/2007

Repos Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 001-15281

Delaware
(State or other jurisdiction of
incorporation)

76-0233274
(IRS Employer
Identification No.)

2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal executive offices, including zip code)

(281) 719-3400
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

Information to be included in the report

Item 8.01. Other Events

Repros Therapeutics Inc. announced today that it plans to publicly offer 2,500,000 shares of its common stock pursuant to an effective registration statement previously filed with the Securities and Exchange Commission.

A copy of the Company's press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

Item 9.01. Financial Statements and Exhibits

c. Exhibits

Exhibit

Number	Description
99.1	Press Release dated January 22, 2007.

Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Repros Therapeutics Inc.

Date: January 22, 2007

By: /s/ Louis Ploth Jr.

Louis Ploth Jr.
Vice President, Business Development and Chief Financial
Officer

Exhibit Index

Exhibit No.	Description
EX-99.1	Press Release dated January 22, 2007.